Ticker brief
OSTX
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
6
authors 14d
5
crowd 14d
+0.42
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-10-06 → 2026-10-07 · now +0.08 (−1 bearish … +1 bullish)
Who spoke5
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @OzmosiHealth | C | · | 2 | +0.08 |
| @Greatstockpix | C | -1.40 | 1 | +0.45 |
| @OpenOutcrier | C | · | 1 | +0.65 |
| @BiopharmIQ | B | · | 1 | +0.40 |
| @CHItrader | B | -0.22 | 1 | +0.40 |
Recent signals6of 6 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-07 | @OzmosiHealth | +0.00 | Reports Phase 2 OST31-164 results were presented on 2026-10-06. | · | tweet ↗ |
| 2026-10-07 | @OzmosiHealth | +0.15 | Reports USDA feedback on the regulatory pathway for OST-HER2. | · | tweet ↗ |
| 2026-10-06 | @CHItrader | +0.40 | OS Therapies reports significant three-year survival results for a bone-cancer treatment. | · | tweet ↗ |
| 2026-10-06 | @BiopharmIQ | +0.40 | Biotech mover list quantifies positive opening reactions to coverage, clinical and regulatory updates. | · | tweet ↗ |
| 2026-10-06 | @OpenOutcrier | +0.65 | Reports statistically significant three-year survival benefit in a Phase 2b osteosarcoma trial. | · | tweet ↗ |
| 2026-10-06 | @Greatstockpix | +0.45 | Reports statistically significant three-year survival results from an OSTX Phase 2b trial. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.